Not only did primary analysis reveal reduced death from cardiovascular causes and non-fatal myocardial infarction overall, but prespecified secondary analysis also showed that, among patients with atherosclerotic disease and heart failure, there were reduced composite heart failure hospitalizations and cardiovascular deaths among patients taking semaglutide
Men with a history of medullary thyroid carcinoma, type 2 diabetes with severe gastroparesis, or significant cardiovascular disease
Teng RL, Wang H, Sun BC, Cai DP, He YM
AA, S., IN, I., MS, K., VB, P., & GL, S
Additionally, BPC-157 has been shown to improve gut health, which is essential for overall well-being